Posts

4 years after FDA snub, GSK partnership propels Spero’s Utebzi across approval finish line

on

Ascidian and Lilly Ink Up‑to‑$1.9B Pact for RNA Exon Editing in Genetic Kidney Diseases

on

Travere pays Everest $112.5M upfront to grow rare kidney disease pipeline

on

BeOne Medicines Signs $2B Deal for Preclinical Trispecific Antibody Option with China's Huahui Health

on

Eli Lilly Licenses CSL's Clazakizumab IL-6 Antibody for $100 Million

on

Eisai Licenses Nuvation Bio's Taletrectinib for ROS1+ Lung Cancer in Europe and Asia

on

MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene

on

Kowa Secures Expanded Rights to Nicox's Glaucoma Drug NCX 470 in Major Global Deal

on

GSK's ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment

on

Sanofi Licenses Formation Bio's JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

on

Kaken Secures Japanese Rights for Alumis' Novel TYK2 Inhibitor ESK-001

on

Merck Acquires Rights to Hengrui's Oral Lp(a) Inhibitor in $2B Deal

on

Merck Secures $2B Deal with China's Hengrui for Novel Heart Drug

on

Servier Acquires Rights to Black Diamond's Solid Tumor Drug BDTX-4933 in $780M Deal

on

AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes

on

Ono Pharmaceutical Acquires Global Rights to Ionis' Sapablursen for Polycythemia Vera in $940M Deal

on

Novartis Secures Global Rights to Kyorin's KRP-M223 for Allergic and Inflammatory Diseases

on